NCT00030303

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: UConn Health · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.

Detailed description

OBJECTIVES: * Determine the feasibility of vaccination with autologous heat shock protein 70 in patients with chronic phase chronic myelogenous leukemia. * Determine the toxicity of this vaccination in these patients. OUTLINE: Patients undergo leukapheresis to obtain peripheral mononuclear cells (PMNCs). Heat shock protein 70 (HSP70) is derived from the autologous PMNCs. Patients receive HSP70 intradermally once weekly for 8 weeks. Patients are followed for 2 weeks.

Conditions

• Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	recombinant 70-kD heat-shock protein

Timeline

• Start date: 2001-01-01
• Primary completion: 2004-01-01
• Completion: 2004-01-01
• First posted: 2003-01-27
• Last updated: 2017-04-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study